Bacteriophage-based nebulizer for upper respiratory health
Stella Maris Therapeutics is developing a bacteriophage-based nebulizer targeting common upper respiratory pathogens. This targeted, non-antibiotic therapy aims to reduce pathogen burden while preserving the microbiome, offering an innovative solution to chronic respiratory conditions.
Overview
Stella Maris Therapeutics presents an innovative solution for upper respiratory health through a bacteriophage-based nebulizer. This approach leverages the exceptional specificity of bacteriophages, viruses that target and kill bacteria without harming the beneficial microbiome. By targeting difficult-to-treat pathogens, this non-antibiotic therapy offers a transformative method to reduce respiratory pathogen load and potentially alleviate chronic conditions such as sinusitis and asthma-related complications.
Technical specifications
- Bacteriophage specificity: Phages are isolated to target specific bacteria, including Pseudomonas, Klebsiella, Staphylococcus, and Streptococcus species.
- Formulations: Developed for injectable, topical, and inhalable applications, with a focus on nebulizer delivery.
- Biofilm disruption: Effective in disrupting biofilms, particularly in chronic sinusitis cases.
- Safety: Phages are generally recognized as safe (GRAS) by the FDA, suitable for use in immunocompromised individuals.
- Device integration: Formulation optimized for use with multiple commercially available nebulization devices.
Technology readiness level
This technology is currently at TRL 4. The project includes phases for phage selection, pre-clinical efficacy validation, formulation, device integration, and potentially a small clinical trial, indicating a solid path towards further development and commercialization.
About Stella Maris Therapeutics
Stella Maris Therapeutics is a biotechnology-focused company that develops and provides butyrate supplements to support gut and brain health. The company utilizes scientific research on the gut-brain axis to create innovative postbiotic solutions. Its flagship product is a high-quality, sodium-based butyrate supplement formulated with a specialized encapsulation strategy, using cellulose and gellan gum to ensure the compound reaches the colon, where it can be effectively utilized by intestinal cells to strengthen the gut barrier and reduce inflammation.
Founded by Dr. Daniel Czyz, an associate professor who studies microbial pathogenesis and neurodegenerative diseases, the company focuses on improving outcomes for individuals dealing with chronic inflammatory and neurodegenerative conditions, including Parkinson’s disease, inflammatory bowel disease, and rheumatoid arthritis. By combining rigorous quality control with a commitment to building relationships with patients and customers, Stella Maris Therapeutics aims to offer evidence-based wellness solutions that address the communication between the digestive system and the nervous system.
Inquire about this partnering listing
Industry applications
delivered to your inbox.